<DOC>
	<DOCNO>NCT02249130</DOCNO>
	<brief_summary>To investigate safety standard triple therapy regimen delavirdine ( DLV ) , zidovudine ( ZDV ) , lamivudine ( 3TC ) follow 14 day experimental treatment regimen tipranavir ( TPV ) without ritonavir ( RTV )</brief_summary>
	<brief_title>Tipranavir Dose-response Study Using Prototype Self-emulsifying Drug Delivery System ( SEDDS ) Formulation Treatment-naive HIV-1 Infected Patients Report Post-study Option , Treatment Triple Therapy With Delavirdine , ZDV 3TC Without Tipranavir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<criteria>HIV1 RNA ≥ 5,000 copies/mL Roche Amplicor assay CD4 cell count ≥ 50 cells/mm3 Karnofsky performance status ≥ 80 Age ≥ 13 year Screening laboratory value indicative adequate baseline organ function , Grade 0 1 laboratory value base ACTG toxicity scale grade . Selected stable [ 2 month longer ] Grade 2 laboratory abnormality subject sponsor 's approval Acceptable medical history physical examination Agreement use barrier contraceptive method least 1 month prior administration study medication , study , 30 day end study Signed informed consent To enter poststudy option , patient complete 14day tipranavir phase trial Previous treatment antiretroviral drug 2 week Clinically significant , active and/or acute ( onset within prior month ) medical problem include opportunistic infection , active cryptococcosis , Pneumocystis carinii pneumonia ( PCP ) , herpes zoster , histoplasmosis cytomegalovirus ( CMV ) , nonopportunistic disease include , limited , progressive multifocal leukoencephalopathy , lymphoma , malignancy require systemic therapy History clinically significant nervous system muscle disease , seizure disorder , psychiatric disorder might impair compliance study Receipt know enzymeinducing drug include rifabutin , rifampin , carbamazepine , dexamethasone , phenobarbital , phenytoin , sulfamidine , sulfinpyrazone , troleandomycin within 30 day prior participation study Receipt investigational medication within 30 day prior participation study Receipt oral contraceptive within 30 day prior participation study Pregnancy lactation ( serum ßhuman chorionic gonadotropin ( ßHCG ) test negative second screen visit tipranavir phase trial ) Evidence active substance abuse , investigator 's opinion , could affect study adherence In investigator 's judgment , inability comply protocol requirement reason specify</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>